期刊
JOURNAL OF INTERNAL MEDICINE
卷 289, 期 2, 页码 259-263出版社
WILEY
DOI: 10.1111/joim.13145
关键词
COVID-19; methylprednisolone; SARS-CoV-2; survival; tocilizumab